OBX-115 is under clinical development by Obsidian Therapeutics and currently in Phase II for Metastatic Melanoma. According to GlobalData, Phase II drugs for Metastatic Melanoma have a 36% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how OBX-115’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
OBX-115 overview
OBX-115 is under development for treatment of solid tumours, cervical cancer, non-small cell lung cancer, metastatic melanoma, head and neck cancer squamous cell carcinoma. The therapy comprises of engineered tumour infiltrating lymphocytes, armoured with regulated membrane-bound IL-15. It is developed based on cytoDRiVE technology. It is administered through intravenous route.
Obsidian Therapeutics overview
Obsidian Therapeutics operates as a biotechnology company developing cell and gene immunotherapies with pharmacologic operating systems for treating cancer and other diseases. The company’s pipeline products include cytoTIL, OBX-115 – melonoma, OBX-115 – additional solid tumors, cytoTIL-X1, cytoTIL-X2, CD40L, IL12, gene editing. It discovers and develops adoptive cell therapies for the treatment of patients with cancer diseases. Obsidian’s cytoDRiVE discovery platform enables rapid optimization of tunable and functional proteins. It partners with with Bristol Myers Squibb (BMS) and Vertex Pharmaceuticals in leveraging its cytoDRiVE platform technology. Obsidian Therapeutics is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of OBX-115’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
